NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ...

A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com/events-and-presentations. A replay of the ...

Sana will present at Citi’s 2025 Global Healthcare Conference at 2:30 p.m. ET on Tuesday, December 2, 2025. Sana will present at the 8 th Annual Evercore Healthcare Conference at 2:35 p.m. ET on ...

Clermont-Ferrand (France), 24 November 2025 (18h30 CET). CARBIOS (Euronext Growth Paris : ALCRB), announces the signing of two new multi-year commercial agreements with major players in beverage ...

Company to deliver a poster presentation on clinical data demonstrating sustained remission following immune checkpoint inhibitor therapy with or after leronlimab treatment in patients with metastatic ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has reached target ...

As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure ...

Importantly, the findings extend beyond the specific antihistamine evaluated in the study. Because the test compound is water-soluble, the demonstrated bioavailability improvement provides a strong ...

CTA311 is an investigational ‘ready-at-point of care’ allogeneic anti-CD19 CAR-T cell therapy designed for B-cell mediated disease. The product candidate incorporates T-cell receptor (TCR) and HLA ...

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia. For more information, visit ...

The DSMB was established in 2023 to oversee the first-in-human aspects of the trial, ensuring ongoing patient safety, data integrity, and scientific validity in line with Clearmind's commitment to ...

The aggregate gross proceeds to the Company from the offering are expected to be approximately $1.5 million, before deducting the placement agent’s fees and other offering expenses payable by the ...